SHR 3680Alternative Names: SHR3680
Latest Information Update: 04 Oct 2016
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Androgen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 01 Sep 2016 Phase-I clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater, Monotherapy) in Australia (PO) (NCT02747342)
- 20 Apr 2016 Jiangsu HengRui Medicine plans a phase I trial for Prostate cancer (Second-line therapy or greater, Metastatic disease, Castration-resistant) in Australia (PO) (NCT02747342)
- 01 Apr 2016 Phase-I/II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease) in China (PO) (NCT02691975)